Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 2275 of 2873 entries
View as:

Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Phase: N/A Priority: Normal
NCT ID: NCT00402558 Org: User:
Start: 05/31/06 End: 04/30/14 Due: 04/30/15

A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)

Phase: N/A Priority: Normal
NCT ID: NCT06113302 Org: User:
Start: 03/01/24 End: 06/02/26 Due: 06/02/27

Study of Erlotinib in Combination With Dasatinib

Phase: N/A Priority: Normal
NCT ID: NCT00895128 Org: User:
Start: 04/30/09 End: - Due: -

Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04266912 Org: User:
Start: 03/17/20 End: 12/31/25 Due: 12/31/26

TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors

Phase: N/A Priority: Normal
NCT ID: NCT06801041 Org: User:
Start: 06/01/25 End: 03/31/29 Due: 03/31/30

Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02520154 Org: User:
Start: 07/05/16 End: 05/22/25 Due: 05/22/26

Olaparib in Treating Patients With Stage IV Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02677038 Org: User:
Start: 11/11/16 End: 07/18/22 Due: 07/18/23

Phase l/II Study of Ruxolitinib for Acute Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01251965 Org: User:
Start: 12/31/10 End: 07/31/12 Due: 07/31/13

Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis

Phase: N/A Priority: Normal
NCT ID: NCT02784496 Org: User:
Start: 09/29/16 End: 01/23/24 Due: 01/23/25

Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML)

Phase: N/A Priority: Normal
NCT ID: NCT00398983 Org: User:
Start: 08/31/06 End: 05/31/12 Due: 05/31/13

Bortezomib in Treating Patients With Chronic Myelogenous Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00023881 Org: User:
Start: 07/02/01 End: 03/31/05 Due: 03/31/06

Using Social Networks to Promote Physical Activity in African American and Hispanic Women

Phase: N/A Priority: Normal
NCT ID: NCT03199196 Org: User:
Start: 05/02/14 End: 05/30/26 Due: 05/30/27

Identifying Decision Making Needs for Older Adult Women with Stage I-III Breast Cancer Considering Neoadjuvant or Adjuvant Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT05049746 Org: User:
Start: 08/23/16 End: 08/23/25 Due: 08/23/26

Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT01339871 Org: User:
Start: 04/20/11 End: 06/07/17 Due: 06/07/18

Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients

Phase: N/A Priority: Normal
NCT ID: NCT01169753 Org: User:
Start: 05/31/11 End: 02/28/13 Due: 02/28/14

Measurement of Digital Colposcopy for Fluorescence Spectroscopy of TNC Using a Second Device

Phase: N/A Priority: Normal
NCT ID: NCT00503919 Org: User:
Start: 05/31/07 End: 02/28/09 Due: 02/28/10

Effect of Physician Attire on Patients' Preference of Physician

Phase: N/A Priority: Normal
NCT ID: NCT03168763 Org: User:
Start: 09/25/17 End: 10/26/20 Due: 10/26/21

Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02983578 Org: User:
Start: 03/02/17 End: 08/30/25 Due: 08/30/26

Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Phase: N/A Priority: Normal
NCT ID: NCT02464657 Org: User:
Start: 07/31/15 End: 05/07/20 Due: 05/07/21

Six-Minute Walk Test in Patients at High Risk for Complications From Lung Resection

Phase: N/A Priority: Normal
NCT ID: NCT00450125 Org: User:
Start: 02/28/07 End: 06/30/20 Due: 06/30/21

Regorafenib and Cetuximab in Patients With Advanced Malignancy

Phase: N/A Priority: Normal
NCT ID: NCT02095054 Org: User:
Start: 03/19/14 End: 03/27/20 Due: 03/27/21

Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00038610 Org: User:
Start: 03/31/01 End: 07/31/14 Due: 07/31/15

Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00081861 Org: User:
Start: 03/31/04 End: 09/30/07 Due: 09/30/08

Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors

Phase: N/A Priority: Normal
NCT ID: NCT04990726 Org: User:
Start: 12/05/19 End: 02/02/27 Due: 02/02/28

Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial

Phase: N/A Priority: Normal
NCT ID: NCT01217931 Org: User:
Start: 01/19/11 End: 01/31/26 Due: 01/31/27